Kisspeptin: The Receptor Break That Revealed How Puberty Starts
No kisspeptin-based drug has been approved for a person to take, anywhere, as of today. What exists instead is one of the strongest human-genetics stories in reproductive medicine: break one receptor and puberty and fertility never start; give the hormone back and the signal that starts them returns within minutes, measured directly in people. That is the honest place to begin — solid human mechanism, real human dosing data from research units, and no finished product a doctor can prescribe.
One disclosure, because it should change how you read what follows. The operator of this site has a commercial interest in compounds described here, including this one. Weigh each claim below against the source attached to it, not against the tone of the page.
Breaking one receptor stopped puberty in two families
In 2003, researchers studying children who never went through puberty on their own found the same broken gene in two unrelated families: KISS1R, the receptor that kisspeptin binds to. George and Seminara describe what followed in a 2012 review: "Soon thereafter a large array of experimental studies began assembling genetic, expression, physiologic, transgenic, knockdown, and electrophysiological data to characterize the physiology of kisspeptin and its seminal role in modulating GnRH release" (PMID 23015291). Mice bred without a working copy of the same receptor failed to mature sexually in the identical way — the same broken switch, in a different species, producing the same outcome.
Kisspeptin sits at the top of the fertility relay
Fertility runs on a three-step relay inside the body: the brain releases a hormone called GnRH in short pulses, GnRH tells the pituitary gland to release two more hormones — LH and FSH — and those two drive testosterone or estrogen production and egg or sperm development. Kisspeptin controls the first step: whether GnRH gets released at all. "Hypothalamic kisspeptin neurons serve as the nodal regulatory centre of reproductive function," writes Victor Navarro in a 2020 review, describing kisspeptin cells as the point where the entire system either fires or stays silent (PMID 32427949).
Starvation and stress reach the reproductive system through this one hormone
The same review explains why a body that is starved of food, or under heavy physical or emotional stress, stops menstruating or loses sex drive: metabolic signals bear down on kisspeptin production before they touch anything else in the chain. A companion chapter on the causes of lost periods puts the wiring in blunter terms: "Neuroendocrine regulation of ovulation involves the interaction between neurons secreting GABA, kisspeptin, and neurokinin which modulate the function of GnRH neurons" (PMID 25905176). The same chapter ties that circuit to the two hormones that track body fat and hunger, leptin and ghrelin — the body checking whether there is enough stored energy on hand before it lets the reproductive system run.
Stress-related loss of periods is where clinical interest concentrates
The clearest present-day medical target is functional hypothalamic amenorrhea — periods that stop from a combination of stress, calorie restriction, and exercise, with no other disease found. A 2022 review places kisspeptin near the top of the list of signals controlling that shutdown: "Various neurotransmitters acting in the central nervous system are involved in control of the HPO axis and of these, kisspeptin is one of the most important" (PMID 36103784). The same paper points toward where treatment research is heading rather than where it has landed: toward drugs built to copy kisspeptin's receptor signal, still in development.
Longer-acting copies are already running in human trials
Natural kisspeptin breaks down in the bloodstream within minutes, which rules it out as a once-daily medicine on its own. That has pushed research toward longer-acting copies of the same signal and blockers of the related neurokinin B pathway. A 2017 review of the field states: "Various Kp/NkB agonist/antagonist compounds have been developed during the last ten years, and are currently being evaluated in humans" (PMID 29157487) — for menopausal hot flushes, for puberty disorders, and as fertility-treatment support. Evaluated in humans is a specific claim: trials are running; regulators have not signed off on a result.
What that leaves you with
Kisspeptin is a real, precisely mapped human hormone with a discovery story as solid as any in endocrinology: break the receptor and puberty never starts; restore the signal and the pulse returns. What it is not, today, is an approved medicine. Every human study cited here measured a hormone response inside a research unit, under monitoring, over hours — not a course a person runs at home over weeks. Choosing to use a compound sold under this name is choosing to run ahead of that trial data, not alongside it.
Ask this article · 2 suggested prompts
Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.